IBD serological panels: Facts and perspectives
Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivi...
Gespeichert in:
| Veröffentlicht in: | Inflammatory bowel diseases 2007-12, Vol.13 (12), p.1561-1566 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1566 |
|---|---|
| container_issue | 12 |
| container_start_page | 1561 |
| container_title | Inflammatory bowel diseases |
| container_volume | 13 |
| creator | Peyrin‐Biroulet, Laurent Standaert‐Vitse, Annie Branche, Julien Chamaillard, Mathias |
| description | Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology.
(Inflamm Bowel Dis 2007) |
| doi_str_mv | 10.1002/ibd.20226 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902334076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902334076</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3806-3cdbc5304b8696956075c17aea4fd904a8d7cf0de6229ddda3f7ba4a1cc738093</originalsourceid><addsrcrecordid>eNp9kD1PwzAQQC0EoqUw8AdQJhBD2vN3zAaFQqVKLDBbju2gILcJcQvqv8cllZhAHs7D09PdQ-gcwxgDkEldujEBQsQBGmJORc4Kxg7TH2SRg1LFAJ3E-J7Q9NQxGmApqOCCD9F4fnefRd81oXmrrQlZa1Y-xJtsZuw6ZmblstZ3sfV2XX_6eIqOKhOiP9vPEXqdPbxMn_LF8-N8ervILS1A5NS60nIKrCyEEooLkNxiabxhlVPATOGkrcB5QYhyzhlaydIwg62VSaDoCF313rZrPjY-rvWyjtaHkLZrNlErIJQySGeM0OW_pCg4gCQ75XUP2q6JsfOVbrt6abqtxqB3GXXKqH8yJvZiL92US-9-yX23BEx64KsOfvu3Sae8vfIbZvl6JQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68500729</pqid></control><display><type>article</type><title>IBD serological panels: Facts and perspectives</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Peyrin‐Biroulet, Laurent ; Standaert‐Vitse, Annie ; Branche, Julien ; Chamaillard, Mathias</creator><creatorcontrib>Peyrin‐Biroulet, Laurent ; Standaert‐Vitse, Annie ; Branche, Julien ; Chamaillard, Mathias</creatorcontrib><description>Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology.
(Inflamm Bowel Dis 2007)</description><identifier>ISSN: 1078-0998</identifier><identifier>EISSN: 1536-4844</identifier><identifier>DOI: 10.1002/ibd.20226</identifier><identifier>PMID: 17636565</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antibodies ; Antibodies, Bacterial - blood ; Antibodies, Fungal - blood ; Autoantigens ; Candida albicans ; Crohn's disease ; diagnostic ; Digestive tract ; Epidemiology ; Humans ; Immune response ; Inflammatory bowel diseases ; Inflammatory Bowel Diseases - diagnosis ; Intestine ; Mutation ; NOD2 protein ; Serologic Tests - methods ; serology ; stratification ; ulcerative colitis</subject><ispartof>Inflammatory bowel diseases, 2007-12, Vol.13 (12), p.1561-1566</ispartof><rights>Copyright © 2007 Crohn's & Colitis Foundation of America, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3806-3cdbc5304b8696956075c17aea4fd904a8d7cf0de6229ddda3f7ba4a1cc738093</citedby><cites>FETCH-LOGICAL-c3806-3cdbc5304b8696956075c17aea4fd904a8d7cf0de6229ddda3f7ba4a1cc738093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fibd.20226$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fibd.20226$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17636565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peyrin‐Biroulet, Laurent</creatorcontrib><creatorcontrib>Standaert‐Vitse, Annie</creatorcontrib><creatorcontrib>Branche, Julien</creatorcontrib><creatorcontrib>Chamaillard, Mathias</creatorcontrib><title>IBD serological panels: Facts and perspectives</title><title>Inflammatory bowel diseases</title><addtitle>Inflamm Bowel Dis</addtitle><description>Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology.
(Inflamm Bowel Dis 2007)</description><subject>Antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Fungal - blood</subject><subject>Autoantigens</subject><subject>Candida albicans</subject><subject>Crohn's disease</subject><subject>diagnostic</subject><subject>Digestive tract</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Inflammatory bowel diseases</subject><subject>Inflammatory Bowel Diseases - diagnosis</subject><subject>Intestine</subject><subject>Mutation</subject><subject>NOD2 protein</subject><subject>Serologic Tests - methods</subject><subject>serology</subject><subject>stratification</subject><subject>ulcerative colitis</subject><issn>1078-0998</issn><issn>1536-4844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQQC0EoqUw8AdQJhBD2vN3zAaFQqVKLDBbju2gILcJcQvqv8cllZhAHs7D09PdQ-gcwxgDkEldujEBQsQBGmJORc4Kxg7TH2SRg1LFAJ3E-J7Q9NQxGmApqOCCD9F4fnefRd81oXmrrQlZa1Y-xJtsZuw6ZmblstZ3sfV2XX_6eIqOKhOiP9vPEXqdPbxMn_LF8-N8ervILS1A5NS60nIKrCyEEooLkNxiabxhlVPATOGkrcB5QYhyzhlaydIwg62VSaDoCF313rZrPjY-rvWyjtaHkLZrNlErIJQySGeM0OW_pCg4gCQ75XUP2q6JsfOVbrt6abqtxqB3GXXKqH8yJvZiL92US-9-yX23BEx64KsOfvu3Sae8vfIbZvl6JQ</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Peyrin‐Biroulet, Laurent</creator><creator>Standaert‐Vitse, Annie</creator><creator>Branche, Julien</creator><creator>Chamaillard, Mathias</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200712</creationdate><title>IBD serological panels: Facts and perspectives</title><author>Peyrin‐Biroulet, Laurent ; Standaert‐Vitse, Annie ; Branche, Julien ; Chamaillard, Mathias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3806-3cdbc5304b8696956075c17aea4fd904a8d7cf0de6229ddda3f7ba4a1cc738093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Fungal - blood</topic><topic>Autoantigens</topic><topic>Candida albicans</topic><topic>Crohn's disease</topic><topic>diagnostic</topic><topic>Digestive tract</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Inflammatory bowel diseases</topic><topic>Inflammatory Bowel Diseases - diagnosis</topic><topic>Intestine</topic><topic>Mutation</topic><topic>NOD2 protein</topic><topic>Serologic Tests - methods</topic><topic>serology</topic><topic>stratification</topic><topic>ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peyrin‐Biroulet, Laurent</creatorcontrib><creatorcontrib>Standaert‐Vitse, Annie</creatorcontrib><creatorcontrib>Branche, Julien</creatorcontrib><creatorcontrib>Chamaillard, Mathias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Inflammatory bowel diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peyrin‐Biroulet, Laurent</au><au>Standaert‐Vitse, Annie</au><au>Branche, Julien</au><au>Chamaillard, Mathias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IBD serological panels: Facts and perspectives</atitle><jtitle>Inflammatory bowel diseases</jtitle><addtitle>Inflamm Bowel Dis</addtitle><date>2007-12</date><risdate>2007</risdate><volume>13</volume><issue>12</issue><spage>1561</spage><epage>1566</epage><pages>1561-1566</pages><issn>1078-0998</issn><eissn>1536-4844</eissn><abstract>Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology.
(Inflamm Bowel Dis 2007)</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17636565</pmid><doi>10.1002/ibd.20226</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0998 |
| ispartof | Inflammatory bowel diseases, 2007-12, Vol.13 (12), p.1561-1566 |
| issn | 1078-0998 1536-4844 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902334076 |
| source | MEDLINE; Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Antibodies Antibodies, Bacterial - blood Antibodies, Fungal - blood Autoantigens Candida albicans Crohn's disease diagnostic Digestive tract Epidemiology Humans Immune response Inflammatory bowel diseases Inflammatory Bowel Diseases - diagnosis Intestine Mutation NOD2 protein Serologic Tests - methods serology stratification ulcerative colitis |
| title | IBD serological panels: Facts and perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A07%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IBD%20serological%20panels:%20Facts%20and%20perspectives&rft.jtitle=Inflammatory%20bowel%20diseases&rft.au=Peyrin%E2%80%90Biroulet,%20Laurent&rft.date=2007-12&rft.volume=13&rft.issue=12&rft.spage=1561&rft.epage=1566&rft.pages=1561-1566&rft.issn=1078-0998&rft.eissn=1536-4844&rft_id=info:doi/10.1002/ibd.20226&rft_dat=%3Cproquest_cross%3E902334076%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68500729&rft_id=info:pmid/17636565&rfr_iscdi=true |